InnoCare (诺诚健华) IPO: Momentum Matters but Mind the Limited Upside
InnoCare launched book building to raise up to USD 288 million to list in Hong Kong. In our previous notes, we have covered the company’s key...
686 Views
InnoCare (诺诚健华) Pre-IPO: PHIP and Valuation Update
InnoCare Pharma Limited is a clinical-stage biopharmaceutical company with a focus on small molecule inhibitors for BTK, and FGFRs. The company...
708 Views
InnoCare (诺诚健华) Pre-IPO: Thoughts on Valuation
InnoCare Pharma Limited is a clinical-stage biopharmaceutical company with a focus on small molecule inhibitors for BTK, and FGFRs. The company...
701 Views
Aequitas 2019 IPOs and Placements Performance - Things We Got Right/Wrong and Things We Plan to Do
2019 marked our first full year of operations as an Independent Research Company, post spin-off from Smartkarma in August 2018. With our...
804 Views
SinoMab (中国抗体) Post-IPO Trading: Decent Retail Interests Can't Save the Day
SinoMab's IPO was priced at the low end and started trading today. We have highlighted in our earlier note that 1) the company's core product...
512 Views